Tech Company Financing Transactions
Mantra Bio Funding Round
On 1/4/2023, Mantra Bio secured $9 million in Series A funding from Samsung Securities, 8VC and Allen & Company.
Transaction Overview
Company Name
Announced On
1/4/2023
Transaction Type
Venture Equity
Amount
$9,000,000
Round
Series A
Investors
Proceeds Purpose
The new Series A-2 funds will enable Mantra Bio to advance our lead development candidate through IND enabling studies. The support from Samsung Securities and our existing investors is a strong vote of confidence in the potential of our platform, our therapeutic pipeline strategy, and our progress.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
600 Gateway Boulevard, South
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Mantra Bio is harnessing exosomes to deliver safe, highly targeted medicines. We are the creator of REVEAL�, an exosome engineering platform combining computational biology and lab automation to generate targeted exosome vehicles (TEVs) for a broad set of therapeutic areas.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alex Mok
Chief Financial Officer
Ed O'Sullivan
Browse more venture capital transactions:
Prev: 1/4/2023: SirionLabs venture capital transaction
Next: 1/4/2023: Puffin Drinkwear venture capital transaction
Share this article
About Our VC Transactions Data
We report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs